Delivery Order SPE2DB20D2104-SPE2DB23FT99J

Award Date 6/14/23
Potential Completion Date 6/15/23
Potential Value $1.4K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $16,715.52, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Telmisartan 80 mg tablets, a medication used to treat high blood pressure and heart failure. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
This federal contract award, valued at $1,275.43, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Telmisartan 80 mg tablets, a medication used to treat high blood pressure and heart failure. The award is a Delivery Order under an existing Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $1,277.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Telmisartan 80 mg tablets, a medication used to treat high blood pressure. The contract is a Delivery Order issued under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $1,832.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Telmisartan 80 mg tablets, a medication used to treat high blood pressure. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $5,634.62 firm fixed-price delivery order is for the supply of Telmisartan 80 mg tablets, a medication used to treat high blood pressure and heart failure. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves...
This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,487.86 firm fixed-price delivery order is for the supply of Telmisartan 80 mg tablets, a medication used to treat high blood pressure. The contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,405.85 firm-fixed-price delivery order is for the supply of Telmisartan 80 mg tablets, a medication used to treat high blood pressure. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., to provide a comprehensive range of...
This federal contract award, valued at $13,142.31, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Telmisartan 80 mg Tablets in 30s, a medication used to treat high blood pressure and heart failure. The contract is a Firm Fixed Price Delivery Order with a completion date of November 26, 2024. This award is part of a larger Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,110.40 Firm Fixed Price delivery order is for Telmisartan 80 mg tablets, a medication used to treat high blood pressure and heart failure. The contract has an ultimate completion date of August 15, 2023 and was awarded on August 14, 2023. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,482.27 firm fixed-price delivery order is for the supply of Telmisartan-HCTZ 40-12.5 mg tablets, a medication used to treat high blood pressure. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB23FT99J
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,364.54 firm-fixed-price delivery order covers the supply of Telmisartan 80 mg tablets, a medication used to treat high blood pressure and heart failure.

The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., valued at up to $999,999,999.00. This IDC serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 11:41 AM